MAGEA2 and melanoma: In melanoma cell lines, guadecitabine and DAC vs. AZA treatment induced the expression of MAGE-A2 in 100% (3/3) and 66.6% (2/3) vs. 33.3% (1/3); of MAGE-A4 in 66.6% (8/12) and 66.6% (8/12) vs. 25% (3/12); of MAGE-A10 in 42.8% (3/7) and 42.8% (3/7) vs. 42.8% (3/7); of GAGE1-2 in 100% (6/6) and 100% (6/6) vs. 83.3% (5/6); of SSX1-2 in 76.9% (10/13) and 76.9% (10/13) vs. 38.4% (5/13) and of SSX1-5 in 100% (10/10) and 100% (10/10) vs. 70% (7/10) (Table 1).